Skip to main content
. 2022 Mar 25;2022:2659714. doi: 10.1155/2022/2659714

Figure 2.

Figure 2

Percentage of eyes with intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED) size after therapy with three injections of brolucizumab in patients with exudative age-related macular degeneration (AMD). The figure shows the change in IRF, SRF, and PED at baseline (week 0), 8 weeks (week 16), and 12 weeks (week 20) after three monthly loading doses of brolucizumab. ∗∗p < 0.01.